Fact sheet: FL AXA Fram Health EP

Fund information
Fund name
FL AXA Framlington Health EP
Fund manager company
Friends Life
Fund type
Pension Fund
Fund managers
  • Dani Saurympersince 31/03/2015
Underlying fund
AXA Framlington Health
Fund objective
AXA state that the aim of the fund is to generate capital growth through investment in healthcare and medical services and product companies worldwide. Investment will be in producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers and other healthcare services companies.
Benchmark
  • MSCI World Healthcare
Investment style
No data available.
Investment method
No data available.
Quick stats
1 Year return
8%
1 Year rank in sector
237/513
Sector
PN Specialist
Yield
-
Fund size
£2m (£2m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
137
Bid price
338.3
Offer price
338.3
Top in this sector
Fund name1 Year
OMW Neptune Rus + Grtr Rus39.8%
ReAssure AL NptRu&GtrRus Pn39.2%
L&G Nep Russia&Gtr Russia Pn39%
Scot Eq JPM Emg Eur Eq Pn36.3%
OMW InvescoPerpetualEmgEurpn34.6%
...more in PN Specialist

Performance snapshot

Holdings snapshot

  • North America69.2%
    Europe ex UK13.2%
    UK9.4%
    Money Market3.6%
    Japan3.3%
  • Biotechnology/Medical30.4%
    Pharmaceuticals27.4%
    Health Care17.7%
    Healthcare & Medical Products16.6%
    Money Market3.6%
  • North American Equities69.2%
    Europe ex UK Equities13.2%
    UK Equities9.4%
    Money Market3.6%
    Japanese Equities3.3%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund0.6%-5%2.5%8%50.3%130.6%
Sector-0.9%-0.9%6%8.2%20.2%40.8%
Rank within sector85 / 546498 / 544339 / 531237 / 51326 / 38610 / 317
Quartile1st4th3rd2nd1st1st
Calendar performance
 YTD - 20162015201420132012
Fund1.9%11.7%29.9%34%12.2%
Sector8.2%2%7.2%11%7.7%
Rank within sector378 / 51415 / 45013 / 38814 / 35772 / 318
Quartile3rd1st1st1st1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
4.22
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.85
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.83
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
14.81
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
11.08
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.8
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.56
Price movement
52 week high385.1
52 week low286.4
Current bid price338.3
Current offer price338.3
Current mid price-
Region
1North America69.24%
2Europe ex UK13.22%
3UK9.44%
4Money Market3.55%
5Japan3.26%
6Global Emerging Markets1.29%
Industry sector
1Biotechnology/Medical30.41%
2Pharmaceuticals27.35%
3Health Care17.68%
4Healthcare & Medical Products16.59%
5Money Market3.55%
6Hospital1.84%
7Food & Drug Retailers1.55%
8Conglomerates1.03%
Asset type
1North American Equities69.24%
2Europe ex UK Equities13.22%
3UK Equities9.44%
4Money Market3.55%
5Japanese Equities3.26%
6Global Emerging Market Equities1.29%
Individual holdings
1ROCHE HLDG AG5%
2GLAXOSMITHKLINE PLC4.6%
3ALLERGAN PLC4.2%
4GILEAD SCIENCES INC4.2%
5UNITEDHEALTH GROUP INC4.2%
6CELGENE CORP4%
7MEDTRONIC INC3.7%
8LILLY (ELI) & CO3.5%
9ABBVIE INC3.3%
Management
Fund manager group
Friends Life
Fund manager company
Friends Life
Fund type
Pension Fund
Fund objective
AXA state that the aim of the fund is to generate capital growth through investment in healthcare and medical services and product companies worldwide. Investment will be in producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers and other healthcare services companies.
Benchmark
  • MSCI World Healthcare
Investment style
No data available.
Investment method
No data available.
Fund managers
NameSinceBiography
Dani Saurymper31/03/2015Dani Saurymper joined AXA IM in April 2015 as Portfolio Manager for the AXA Framlington Health funds. Dani has 14 years’ experience. Prior to joining AXA IM in April 2015 as Portfolio Manager, he was a senior equity research analyst covering European Healthcare at Barclays Capital. Dani started his career at Goldman Sachs as a senior pharmaceutical analyst covering European Pharmaceuticals, before moving to Nomura as a sector specialist covering global healthcare Dani graduated from Leeds University with a BSc in Management Studies and Pharmacology and holds an MSc in International Business from the Manchester School of Management, UMIST.
Compliance
No data available.
Domicile
No data available.
Fund for sale in
United Kingdom
FL AXA Framlington Health EP
Initial charge-
Annual charge1.25%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)1.33%
Bid price338.3
Offer price338.3
Mid price-
CurrencyGBX
Price updated05/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeWK25
FL AXA Framlington Health EP S3
Initial charge-
Annual charge1.25%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)1.33%
Bid price338.3
Offer price338.3
Mid price-
CurrencyGBX
Price updated05/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeW235
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.